Epidrugs: Targeting Epigenetic Marks in Cancer Treatment

Overview

Journal Epigenetics

Specialty Genetics

Date 2019 Jul 9

PMID 31282279

Citations 127

Authors

Cristiana Libardi Miranda Furtado

Maria Claudia Dos Santos Luciano

Renan da Silva Santos

Gilvan Pessoa Furtado

Manoel Odorico Moraes

Claudia Pessoa

Affiliations

Soon will be listed here.

Abstract

Growing evidence suggests that aberrant epigenetic regulation of gene function is strongly related to the genesis of cancer. Unlike genetic mutations, the ability to reprogram the epigenetic landscape in the cancer epigenome is one of the most promising target therapies in both treatment and reversibility of drug resistance. Epigenetic alterations in cancer development and progression may be the basis for the individual variation in drug response. Thus, this review focuses on the emerging area of pharmaco(epi)genomics, specifically highlighting epigenetic reprogramming during tumorigenesis and how epigenetic markers are targeted as a therapy (epidrugs) and the clinical implications of this for cancer treatment.

Citing Articles

Design, synthesis and evaluation of pyrimidinobenzylamide and pyrimidinothiophenamide derivatives as inhibitors of DOT1L and related epigenetic targets DNMT3a, PRMT4 and other HMTs.

Castillo-Aguilera O, Depreux P, Halby L, Bailly C, Dominguez-Ramirez L, Gul S RSC Med Chem. 2025; .

PMID: 40061000 PMC: 11886420. DOI: 10.1039/d4md00899e.

Advances in epigenetic treatment of adult T-cell leukemia/lymphoma: a comprehensive review.

Letafati A, Mehdigholian Chaijani R, Edalat F, Eslami N, Askari H, Askari F Clin Epigenetics. 2025; 17(1):39.

PMID: 40025589 PMC: 11871821. DOI: 10.1186/s13148-025-01841-z.

Rescuing DNMT1 fails to fully reverse the molecular and functional repercussions of its loss in mouse embryonic stem cells.

Elder E, Lemieux A, Legault L, Caron M, Bertrand-Lehouillier V, Dupas T Nucleic Acids Res. 2025; 53(4).

PMID: 39997223 PMC: 11851107. DOI: 10.1093/nar/gkaf130.

DNMT3a promotes LUAD cell proliferation and metastasis by activating the HDAC7 signalling pathway.

Jiang M, Zhou X, Feng Y, Ding P, Li J, Lu D Int J Biol Sci. 2025; 21(4):1585-1602.

PMID: 39990668 PMC: 11844290. DOI: 10.7150/ijbs.96509.

Promoter Methylation Is Vital for the Anticancer Activity of Withaferin A.

Brane A, Sutko M, Tollefsbol T Int J Mol Sci. 2025; 26(3).

PMID: 39940977 PMC: 11818515. DOI: 10.3390/ijms26031210.

References

Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, Boland C . Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut. 2013; 63(4):635-46. PMC: 3884067. DOI: 10.1136/gutjnl-2012-304219. View

Lyko F . The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2017; 19(2):81-92. DOI: 10.1038/nrg.2017.80. View

Richon V, Garcia-Vargas J, Hardwick J . Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009; 280(2):201-10. DOI: 10.1016/j.canlet.2009.01.002. View

Barata P, Sood A, Hong D . RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev. 2016; 50:35-47. DOI: 10.1016/j.ctrv.2016.08.004. View

Karachaliou N, Fernandez-Bruno M, Rosell R . Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. Transl Lung Cancer Res. 2018; 7(Suppl 3):S198-S201. PMC: 6193917. DOI: 10.21037/tlcr.2018.07.02. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Haig D . The (dual) origin of epigenetics. Cold Spring Harb Symp Quant Biol. 2005; 69:67-70. DOI: 10.1101/sqb.2004.69.67. View

Leick M, Shoff C, Wang E, Congress J, Gallicano G . Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer. Am J Stem Cells. 2013; 1(1):59-74. PMC: 3643389. View

Liu B, Cheng J, Zhang X, Wang R, Zhang W, Lin H . Global histone modification patterns as prognostic markers to classify glioma patients. Cancer Epidemiol Biomarkers Prev. 2010; 19(11):2888-96. DOI: 10.1158/1055-9965.EPI-10-0454. View

10.

Egger G, Liang G, Aparicio A, Jones P . Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429(6990):457-63. DOI: 10.1038/nature02625. View

11.

Werner H, Mills G, Ram P . Cancer Systems Biology: a peek into the future of patient care?. Nat Rev Clin Oncol. 2014; 11(3):167-76. PMC: 4321721. DOI: 10.1038/nrclinonc.2014.6. View

12.

Park J, Han J . Targeting epigenetics for cancer therapy. Arch Pharm Res. 2019; 42(2):159-170. PMC: 6399185. DOI: 10.1007/s12272-019-01126-z. View

13.

Geiman T, Muegge K . DNA methylation in early development. Mol Reprod Dev. 2009; 77(2):105-13. DOI: 10.1002/mrd.21118. View

14.

Zhao B, Wang X, Beadell A, Lu Z, Shi H, Kuuspalu A . mA-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition. Nature. 2017; 542(7642):475-478. PMC: 5323276. DOI: 10.1038/nature21355. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Shao Q, Xu J, Deng R, Wei W, Zhou B, Yue C . Long non-coding RNA-422 acts as a tumor suppressor in colorectal cancer. Biochem Biophys Res Commun. 2017; 495(1):539-545. DOI: 10.1016/j.bbrc.2017.10.076. View

17.

Robertson K . DNA methylation, methyltransferases, and cancer. Oncogene. 2001; 20(24):3139-55. DOI: 10.1038/sj.onc.1204341. View

18.

Liu Z, Ding K, Li L, Liu H, Wang Y, Liu C . A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes. Biomed Pharmacother. 2016; 83:1032-1037. DOI: 10.1016/j.biopha.2016.08.023. View

19.

Kim E, Ilagan J, Liang Y, Daubner G, Lee S, Ramakrishnan A . SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell. 2015; 27(5):617-30. PMC: 4429920. DOI: 10.1016/j.ccell.2015.04.006. View

20.

Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C . Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep. 2018; 45(6):2935-2940. DOI: 10.1007/s11033-018-4427-x. View